IN THE CLAIMS:

This listing of claims will replace all prior versions and listing of claims in the application.

Listing of the claims:

Claim 1 (**currently amended**): A compound of formula (I)



(I)



(I)

wherein R^2 is ~~amino,~~ a group OR^4 or a group $-Y-R^5$ where

R^4 is hydrogen or C_{1-4}alkyl,

Y is C_{1-4}alkylene,

R^5 is ~~hydrogen,~~ halo, hydroxy, C_{1-2}alkoxy, C_{1-2}alkoxyC_{1-2}alkoxyC_{1-4}, or a group NR^7R^8 where R^7 and R^8 are independently selected from hydrogen, C_{1-2}alkyl, hydroxyC_{1-2}alkyl or alkoxyC_{1-2}alkyl, or R^7 and R^8 together with the nitrogen atom to which they are attached form a saturated 5-6-membered heterocyclic ring which optionally contains an additional heteroatom;

n is one or two and each R^1 is independently selected from halo, haloC_{1-2}alkyl, hydroxy, ~~oxo,~~ amino, C_{1-2}alkylamino or di-C_{1-2}dialkylamino;

or a pharmaceutically acceptable salt thereof.

Claim 2 (**currently amended**): The ~~A~~ compound according to claim 1 wherein R^2 is a group-Y-R^5.

Claim 3 (**currently amended**): The ~~A~~ compound according to claim 2 wherein Y is a C_{1-2}alkylene group.

Claim 4 (**cancelled**).

Claim 5 (**currently amended**): The ~~A~~ compound according to claim 1 wherein R^2 is a group –Y-R^5 and R^5 is a group NR^7R^8 where R^7 and R^8 are independently selected from hydrogen, C_{1-2}alkyl, hydroxyC_{1-2}alkyl or alkoxyC_{1-2}alkyl, or R^7 and R^8 together with the nitrogen atom to which they are attached form a saturated 5-6-membered heterocyclic ring which optionally contains an additional heteroatoms.

Claim 6 (**currently amended**): The ~~A~~ compound according to claim 1 ~~any one of the preceding claims~~ wherein n is 1.

Claim 7 (**currently amended**): The ~~A~~ compound according to claim 1 ~~any one of the preceding claims~~ wherein at least one R^1 group is a halo group.

Claim 8 (**currently amended**): The ~~A~~ compound according to claim 7 wherein R^1 is bromo or chloro.

Claim 9 (**currently amended**): The ~~A~~ compound according to claim 1 ~~any one of the preceding claims~~ wherein an R^1 group is present at a position equivalent to the 5-position as numbered on the indole ring.

Claim 10 (**currently amended**): The ~~A~~ compound according to claim 1 which is ~~6-{4-[4-(5-Chloro-1H-indole-2-sulphonyl)-piperazine-1-carbonyl]-phenyl}-2-methyl-2H-pyridazin-3-one,~~

~~1-(5-chloroindol-2-ylsulphonyl)-4-[4-(6-oxo-1-methyl-pyridazin-3-yl)-benzoyl]piperazine,~~

6-[4-({4-[(5-chloro-1H-indol-2-yl)sulphonyl]piperazin-1-yl}carbonyl)phenyl]-2-[2-(dimethylamino)ethyl]pyridazin-3(2H)-one,

6-{4-[4-(5-chloro-1H-indole-2-sulfonyl)-piperazine-1-carbonyl]-phenyl}-2-(2-methylamino-ethyl)-2H-pyridazin-3-one,

~~6-{4-[4-(5-chloro-1H-indole-2-sulfonyl)-piperazine-1-carbonyl]-phenyl}-2-ethyl-2H-pyridazin-3-one,~~

~~2-butyl-6-{4-[4-(5-chloro-1H-indole-2-sulfonyl)-piperazine-1-carbonyl]-phenyl}-2H-pyridazin-3-one,~~

6-{4-[4-(5-chloro-1H-indole-2-sulfonyl)-piperazine-1-carbonyl]-phenyl}-2-(2-hydroxy-ethyl)-2H-pyridazin-3-one,

6-{4-[4-(5-chloro-1H-indole-2-sulfonyl)-piperazine-1-carbonyl]-phenyl}-2-(2,2,2-trifluoro-ethyl)-2H-pyridazin-3-one,

6-{4-[4-(5-chloro-1H-indole-2-sulfonyl)-piperazine-1-carbonyl]-phenyl}-2-(2-methoxy-ethyl)-2H-pyridazin-3-one,

6-[4-({4-[(5-chloro-1H-indol-2-yl)sulphonyl]piperazin-1-yl}carbonyl)phenyl]-2-[2-(2-methoxyethoxy)ethyl]pyridazin-3(2H)-one,

6-{4-[4-(5-Chloro-1H-indole-2-sulfonyl)-piperazine-1-carbonyl]-phenyl}-2-fluoromethyl-2H-pyridazin-3-one,

6-{4-[4-(5-Chloro-1H-indole-2-sulfonyl)-piperazine-1-carbonyl]-phenyl}-2-difluoromethyl-2H-pyridazin-3-one or

6-{4-[4-(5-Chloro-1H-indole-2-sulfonyl)-2-oxo-piperazin-1-ylmethyl]-phenyl}-2-(2-morpholin-4-yl-ethyl)-2H-pyridazin-3-one.

Claim 11 (**currently amended**): A process for preparing a compound of formula (I) as defined in claim 1 which process comprises either

(a) reacting an amine of formula (II)



(II)



(II)

with an acid of the formula (III)



(III)

or a reactive derivative thereof; or

(b) reacting a compound of the formula (VIII):



(VIII)

wherein Z' is a displaceable group, with a compound of formula (IX)



(IX)

wherein R^2 is as defined claim 1 and A is an activating group, or

(c) forming a substituted pyridazinone ring on compounds of formula (VIII), wherein Z' is a functional group capable of cyclisation;

(d) by reacting a compound of the formula (X):



(X)

where R^2 is as defined in claim 1, with a compound of the formula (XI):



(XI)

wherein R^1 and n are as defined in claim 1 and Z'' is a displaceable group, under conditions similar to those described above in process (a); or

(e) reacting a compound of formula (XIII)



(XIII)



(XIII)

wherein R^1 and n are as defined claim 1, and the indole ring is optionally protected, with a compound of formula (A)

$$R^2\text{-}Z''' \qquad (A)$$

where R^2 is as defined in claim 1 and Z''' is a displaceable group, and thereafter optionally ~~if necessary,~~ removing any indole protecting groups.

Claim 12 (**cancelled**).

Claim 13 (**original**): A pharmaceutical composition comprising a compound of formula (I), or a pharmaceutically-acceptable salt thereof, as defined in claim 1 or claim 10 ~~any claim from 1 to 8~~, with a pharmaceutically-acceptable diluent or carrier.

Claims 14-15 (**cancelled**).

Claim 16 (**new**): A method for producing an antithrombotic or anticoagulant effect in a warm-blooded animal in need thereof comprising administering an effective amount of a compound of formula (I), as defined in claim 1 or claim 10 ~~any claim from 1 to 10~~, or a pharmaceutically-acceptable salt thereof.